Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Abstract Objective To evaluate the efficacy and safety of PLD in treating of in patients who experience epithelial ovarian, fallopian tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy. Methods This was an open-label, single-arm and multicenter clin...

Full description

Bibliographic Details
Main Authors: Zhen Yuan, Ying Zhang, Dongyan Cao, Keng Shen, Qingshui Li, Guonan Zhang, Xiaohua Wu, Manhua Cui, Ying Yue, Wenjun Cheng, Li Wang, Pengpeng Qu, Guangshi Tao, Jianqing Hou, Lixin Sun, Yuanguang Meng, Guiling Li, Changzhong Li, Huirong Shi, Yaqing Chen
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Journal of Ovarian Research
Subjects:
CA125
Pegylated liposomal doxorubicin
Platinum-refractory relapse
Platinum-resistant relapse
Partially platinum-sensitive relapse
Online Access:https://doi.org/10.1186/s13048-020-00736-2

Internet

https://doi.org/10.1186/s13048-020-00736-2

Similar Items